companies

DiogenX

Founded 2020
Employees 7+
Primary contact
180 avenue du Prado
13008 Marsille
France
Links
https://diogenx.com/
Diseases & Conditions
Sections
DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Its lead program is focused on modulating the Wnt/Ξ²-catenin signaling pathway to regenerate pancreatic insulin-producing beta cells to offer a disease-modifying therapy for type 1 diabetes. It is currently in preclinical development. In addition to its headquarters in Marseille, the company has labs in Nice, France.
Founded 2020
Employees 7+
Primary contact
180 avenue du Prado
13008 Marsille
France
Links
https://diogenx.com/
Diseases & Conditions
Sections

Funding πŸ’°

Total €32M
Last round πŸ”— €27.5M
Series A
May 10, 2023.
Select investors Boehringer Ingelheim Venture Fund, Roche Venture Fund, JDRF T1D Fund, Eli Lilly, AdBio partners, Omnes Capital

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • Big addressable market: In 2019, approximately 463 million adults between the ages of 20-79 were living with diabetes. In the same year, diabetes was the cause of 4.2 million deaths and accounted for €700 billion ($760bn) in health expenditure - 10% of total health spending on adults. By 2045 it is estimated that prevalence in adults will rise to 700 million. There are currently no approved disease modifying therapies for T1D, despite today 18 million people worldwide living with T1D. πŸ”—
  • Potential game changer: Restoring the patient's endogenous beta cells to increase insulin production would be a game-changer for diabetic patients, potentially eliminating the need for exogenous insulin in some patients.
  • Huge potential: DiogenX's drug candidate has the potential to become the first off-the-shelf solution to regenerate pancreatic beta cells and the first disease-modifying treatment against symptomatic type 1 diabetes. πŸ”—

In the news πŸ“°

Marseille, France-based DiogenX gets €27.5M in Series A financing
May 11, 2023

Quotes πŸ’¬

“
Diogenx lead candidate has shown an unprecedented effect in beta cell regeneration in preclinical work. It is a potential breakthrough regenerative therapy aimed at restoring pancreatic function.
— Johannes Zanzinger, investment director at BIVF πŸ”—
“
The JDRD T1D Fund is thrilled to continue its support of the DiogenX program in this important step towards the clinic. Restoring a patient's own pancreatic function without the need for surgery would have a game-changing disease-modifying impact for the T1D community, who currently rely on insulin therapy.
— Katie Ellias, managing director at JDRF T1D Fund πŸ”—
Last update: May 14, 2023